Treatment of autoimmune mucocutaneous blistering diseases with intravenous immunoglobulin therapy (Q35842548)

10 August 2017

1 reference

title

Treatment of autoimmune mucocutaneous blistering diseases with intravenous immunoglobulin therapy (English)

1 reference

10 August 2017

A Razzaque Ahmed

1

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 August 2004

1 reference

Expert Opinion on Investigational Drugs

10 August 2017

published in

1 reference

10 August 2017

volume

13

1 reference

10 August 2017

issue

8

1 reference

10 August 2017

page(s)

1019-1032

1 reference

Pemphigus and bullous pemphigoid

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Epidermolysis bullosa acquisita: a heterogeneous disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

A systematic review of treatments for bullous pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Interventions for mucous membrane pemphigoid/cicatricial pemphigoid and epidermolysis bullosa acquisita: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Emerging treatment for epidermolysis bullosa acquisita

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Diagnostic features of pemphigus vulgaris in patients with pemphigus foliaceus: detection of both autoantibodies, long-term follow-up and treatment responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid: effects on disease progression in patients nonresponsive to dapsone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Cicatricial pemphigoid with circulating IgA and IgG autoantibodies to the central portion of the BP180 ectodomain: beneficial effect of adjuvant therapy with high-dose intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy. Long-term follow-up: influence of treatment on antibody titres to human alpha6 integrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Linear IgA bullous dermatosis in a patient with chronic renal failure: response to intravenous immunoglobulin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Linear IgA bullous disease limited to the eye: a diagnostic dilemma: response to intravenous immunoglobulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Pemphigus vulgaris in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Bullous diseases in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Pemphigus vulgaris in an adolescent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Nonendemic pemphigus foliaceus in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Childhood pemphigus foliaceus: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Pemphigus vulgaris: incidence in Jews of different ethnic groups, according to age, sex, and initial lesion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

A five year retrospective study on pemphigus and pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Comparative study of pemphigus vulgaris and pemphigus foliaceus in Singapore

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Comparative epidemiology of pemphigus in Tunisia and France: unusual incidence of pemphigus foliaceus in young Tunisian women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Endemic pemphigus foliaceus (Fogo Selvagem): II. Current and historic epidemiologic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

21 January 2018

Cicatricial pemphigoid

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Autoimmunity to keratinocyte acetylcholine receptors in pemphigus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

The Correlation between the Antibody Titers in Sera of Patients with Pemphigus Vulgaris and their Clincial State

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Autoimmunity against desmosomal cadherins in pemphigus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Basement zone antibodies in bullous pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Isolation of complementary DNA for bullous pemphigoid antigen by use of patients' autoantibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Some biochemical properties of pemphigoid antigen bound to the surface of dissociated epidermal basal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Upper aerodigestive tract manifestations of cicatricial pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Immunopathology of cicatricial pemphigoid: studies of complement deposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

The Major Cicatricial Pemphigoid Antigen Is a 180-kD Protein that Shows Immunologic Cross-Reactivities with the Bullous Pemphigoid Antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Autoantibodies to human alpha6 integrin in patients with oral pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

New immunomodulating drugs in autoimmune blistering diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Guidelines for the management of bullous pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Pemphigus controlled by dapsone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Update on systemic glucocorticosteroids in dermatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

The events leading to the death of patients with pemphigus and pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Lack of predictive factors for the clinical course of bullous pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Influence of intravenous immunoglobulin therapy on serum levels of anti-beta 4 antibodies in ocular cicatricial pemphigoid. A correlation with disease activity. A preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Dermatological uses of high-dose intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

A new preparation of modified immune serum globulin (human) suitable for intravenous administration. II. Functional characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

Rapid infusion of Sandoglobulin in patients with primary humoral immunodeficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.8.1019

10.1517/13543784.13.8.1019

21 January 2018

Identifiers

DOI

1 reference

release_rr4ki3s6sbcllj7wrovh6vgybu

10 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rr4ki3s6sbcllj7wrovh6vgybu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference